retatrutide 2025 trial results 💉𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲'𝘀 𝗨𝗻𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁: 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂 𝗦𝗵𝗼𝘂𝗹𝗱 𝗞𝗻𝗼𝘄 𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲: a new triple-agonist weight loss drug that is STILL IN CLINICAL TRIALS, is showing incredible results, with some retatrutide news october 2025 A

Regulatory Pathways and Approval Processes FDA Approval Framework The United States Food and Drug Administration (FDA) regulates therapeutic peptides under established frameworks for biological products

In clinical trials, retatrutide has been given as a weekly injection under the skin (subcutaneous)

As I discussed on Episode 80 of our podcast, The Future of GLP-1 Medications: Quick Pen and Dose Flexibility, our dilution approach has allowed patients to reduce their medication costs by a third or even a sixth of the traditional cost

Your prescriber can discuss with you which medication might suit you best

This study found that participants regained a significant portion of lost weight after discontinuing semaglutide: Rubino D et al., Discontinuation of GLP-1 Receptor Agonist Therapy and Weight Regain, Frontiers in Endocrinology , 2021

GLP-1s are powerful medications and should be prescribed only by medical professionals who have completed comprehensive medical assessments, including running labs, adds Zimmermann